MRNA Stock Price, Chart, Stats & News

MRNA chart
Fundamentals
Gross margin | 14.10% |
Operating margin | -158.21% |
Pretax margin | -142.46% |
Net margin | -145.24% |
Effective tax rate | -1.95% |
ROA | -22.87% |
ROE | -30.15% |
D/E | 0.22x |
Interest coverage ratio | -1537.00x |
MRNA valuation
P/E | – |
P/S | 10.07x |
P/B | 2.25x |
P/CF | -10.49x |
P/FCF | -9.53x |
P/OCF | -10.49x |
PEG | -0.69x |
EV multiple | -7.94x |
About
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah.
Similar securities
Based on sector and market capitalization











